# Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD

> **NCT00574470** · PHASE4 · COMPLETED · sponsor: **University of Iowa** · enrollment: 3 (actual)

## Conditions studied

- Graft vs Host Disease

## Interventions

- **DRUG:** daclizumab, infliximab

## Key facts

- **NCT ID:** NCT00574470
- **Lead sponsor:** University of Iowa
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2007-11
- **Final completion:** 2008-08
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2017-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00574470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00574470, "Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00574470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*